Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib PK study in Chinese patients with advanced NSCLC
NCT02529995Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration (Cmax) of AZD9291, AZ5104, and AZ7550 After Single Dosing, Area Under the Plasma Concentration-Time Curve (AUC) of AZD9291, AZ5104, and AZ7550 After Single Dosing and 4 more. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02529995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529995.